Trial Profile
Bi-weekly Cetuximab Combined With FOLFOX-6 as First-line Treatment in Metastatic Colorectal Cancer Patients With Wild-type K-ras Status
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Carcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms CEBIFOX
- 03 Jul 2021 Results of subgroup analyses from EREBUS, ERBITAG and CEBIFOX assessing overall survival with cetuximab every 2 weeks vs standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer APEC presented at the 23rd World Congress on Gastrointestinal Cancer
- 24 Jan 2017 Status changed from active, no longer recruiting to completed.
- 11 Oct 2016 Primary endpoint has been met. (Response rate (RECIST-Criteria))